alpha-aminopyridine has been researched along with Psoriasis in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 17 (89.47) | 2.80 |
| Authors | Studies |
|---|---|
| Lé, AM; Torres, T | 1 |
| Egeberg, A; Gyldenløve, M | 1 |
| Albrecht, L; Bagel, J; Berk, DR; Bhatia, N; Burnett, P; Del Rosso, JQ; Devani, AR; Draelos, ZD; Feng, A; Ferris, LK; Gooderham, MJ; Green, LJ; Hebert, AA; Higham, RC; Jones, T; Kempers, SE; Kircik, LH; Lebwohl, MG; Lomaga, M; Moore, AY; Papp, KA; Pariser, DM; Snyder, S; Stein Gold, L; Yamauchi, PS; Zirwas, M | 1 |
| Cordoro, KM | 1 |
| Egeberg, A; Gyldenløve, M; Meteran, H; Zachariae, C | 2 |
| Feldman, SR; Pixley, JN; Schaetzle, T | 1 |
| Gooderham, MJ; Hebert, AA; Lebwohl, MG | 1 |
| Collier, MR; Smith, B; Wu, JJ | 1 |
| Adam, DN; Berk, DR; Burnett, P; Draelos, ZD; Higham, RC; Hong, HC; Krupa, D; Lebwohl, MG; Lynde, CW; Nahm, WK; Papp, KA; Pariser, DM; Stein Gold, L; Stewart, D | 1 |
| De la Torre Gomar, FJ; Gimeno Castillo, J; Martínez de Lagrán Álvarez de Arcaya, Z; Menéndez Parrón, A | 1 |
| Gooderham, M; O'Toole, A | 1 |
| Berk, DR; Draelos, ZD; Gooderham, MJ; Kempers, SE; Kircik, LH; Lebwohl, MG; Merritt, C; Navale, L; Osborne, DW; Papp, KA; Smith, K; Stein Gold, L; Trotman, ML; Welgus, H; Zirwas, M | 1 |
| Berk, DR; Droege, M; Gooderham, M; Merritt, C; Osborne, DW; Papp, KA; Smith, VH; Thurston, AW; Welgus, H | 1 |
| Kataoka, S; Nakajima, K; Sano, S; Takaishi, M | 1 |
| Mahil, SK; Smith, CH | 1 |
| Goehring, UM; Snape, SD; Wigger-Alberti, W | 1 |
| Burnet, M; Guse, JH; Gutke, HJ; Khobzaoui, M; Renukappa-Gutke, T | 1 |
5 review(s) available for alpha-aminopyridine and Psoriasis
| Article | Year |
|---|---|
New Topical Therapies for Psoriasis.
Topics: Administration, Topical; Aminopyridines; Amygdalin; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dermatologic Agents; Humans; Interleukin-2; MicroRNAs; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrazoles; Pyrimidines; Resorcinols; Stilbenes | 2022 |
A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.
Topics: Adrenal Cortex Hormones; Aminopyridines; Clinical Trials as Topic; Dermatologic Agents; Humans; Immunoglobulin A; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
Oral roflumilast as a therapeutic option for psoriasis, what role does it have? Case report and literature review.
Topics: Administration, Oral; Aminopyridines; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive | 2023 |
Topical Roflumilast for Plaque Psoriasis.
Topics: Adolescent; Adult; Aminopyridines; Benzamides; Emollients; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis | 2023 |
AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Administration, Topical; Amides; Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dermatitis, Atopic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Indoles; Inflammation; Lipopolysaccharides; Ovalbumin; Phosphodiesterase Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Structure-Activity Relationship | 2005 |
4 trial(s) available for alpha-aminopyridine and Psoriasis
| Article | Year |
|---|---|
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Topics: Aminopyridines; Benzamides; Double-Blind Method; Emollients; Humans; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Topics: Administration, Topical; Adult; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream | 2020 |
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Topics: Adult; Aged; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2020 |
A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aminopyridines; Benzamides; Chronic Disease; Cyclopropanes; Dermatologic Agents; Female; Humans; Male; Middle Aged; Ointments; Phosphodiesterase 4 Inhibitors; Psoriasis; Skin Tests; Treatment Outcome; Young Adult | 2016 |
10 other study(ies) available for alpha-aminopyridine and Psoriasis
| Article | Year |
|---|---|
Killing all the birds with one drug - is oral roflumilast a novel treatment option for psoriasis?
Topics: Aminopyridines; Chronic Disease; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive | 2022 |
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pruritus; Psoriasis; Randomized Controlled Trials as Topic; Skin Cream | 2022 |
Roflumilast for Chronic Plaque Psoriasis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis | 2022 |
Long-term clearance of severe plaque psoriasis with oral roflumilast.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclopropanes; Humans; Psoriasis; Severity of Illness Index | 2023 |
Topical roflumilast (Zoryve) for plaque psoriasis.
Topics: Administration, Cutaneous; Administration, Topical; Aminopyridines; Benzamides; Cyclopropanes; Dermatologic Agents; Humans; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
Topics: Administration, Cutaneous; Aminopyridines; Benzamides; Chronic Disease; Cyclopropanes; Double-Blind Method; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2023 |
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
Topics: Administration, Cutaneous; Aminopyridines; Benzamides; Chronic Disease; Cyclopropanes; Double-Blind Method; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2023 |
Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
Topics: Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclic AMP; Cyclopropanes; Down-Regulation; Humans; Inflammation Mediators; Interleukin-18; Interleukin-1alpha; Interleukin-8; Keratinocytes; MAP Kinase Signaling System; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Tumor Necrosis Factor-alpha | 2020 |
In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeks.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Psoriasis; Treatment Outcome | 2020 |
Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Humans; Psoriasis; Severity of Illness Index; Treatment Outcome | 2021 |